Computationally Guided Design of Two Novel Phosphodiesterase-4 Inhibitors for Treatment of Plaque Psoriasis

Abstract

Plaque psoriasis is a chronic inflammatory skin disease characterized by itchy, scaly skin. Although there is currently no cure for this disease, it can be managed with medication, such as phosphodiesterase-4 (PDE4) inhibitors. Current PDE4 inhibitors are limited and show adverse effects. With the goal to develop better PDE4 inhibitors for the treatment of plaque psoriasis, two novel drug candidates were designed with computational studies, and observed to have better ADMET properties compared to Roflumilast. A homology analysis was performed to determine the best model organism for preclinical studies of the novel candidates.

Efficacy of phosphodiesterase-3 (PDE-3) inhibitors for the treatment of cerebral vasospasm in patients with aneurysmal subarachnoid haemorrhage (aSAH) admitted to the intensive care unit (ICU): a systematic review and meta-analysis protocol
Mohammadi Maahtaab, Abubakr El Sheikh Idris, Breffni Smith +3
BMJ Open5 Nov 2026Peer-reviewedLicence not statedGeneral medicineCrossref
Cell Viability of the Administered Product Predicts Response to Stromal Vascular Fraction in Patients with Erectile Dysfunction Unresponsive to Phosphodiesterase Type 5 Inhibitors
Ahmet Semih Güleser, Atakan Eren, Fatih Altunrende +2
Medicina (Kaunas, Lithuania)1 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC
Simulation-guided outlet valve repair: early integration of computationally-derived principles of free-edge length in bicuspidization repair
Perry Seo Choi, Alexander D. Kaiser, Riya Nilkant +5
Frontiers in cardiovascular medicine16 Oct 2026Peer-reviewedCC BYFull textCardiovascular medicineEurope PMC
When Steroids Backfire: Tinea Incognito Following Treatment for Presumed Psoriasis.
Nicole Skalka, Nathaniel Marroquin, Jay Nguyen +2
Cureus21 Sep 2026Peer-reviewedCC BYFull textEpidemiology & public healthEurope PMC
Interplay of Biological Treatment and Psychological Features in Patients with Psoriasis: A Real-Life Prospective Study.
Gaia Moretta, Tonia Samela, Alessia Provini +21
Dermatology practical & conceptual31 Jul 2026Peer-reviewedCC BY-NCFull textGeneral medicineEurope PMC

Cite

BibTeX RIS

BibTeX

@misc{liu2026computationally,
  title = {{Computationally Guided Design of Two Novel Phosphodiesterase-4 Inhibitors for Treatment of Plaque Psoriasis}},
  author = {A. Liu and E. R. M. James and J. B. Siegel},
  howpublished = {bioRxiv},
  year = {2026},
  month = oct,
  doi = {10.64898/2026.10.20.760516},
  url = {https://www.biorxiv.org/content/10.64898/2026.10.20.760516v1},
  note = {CC BY},
}

RIS

TY  - UNPB
TI  - Computationally Guided Design of Two Novel Phosphodiesterase-4 Inhibitors for Treatment of Plaque Psoriasis
AU  - A. Liu
AU  - E. R. M. James
AU  - J. B. Siegel
PY  - 2026
DA  - 2026/10/20
PB  - bioRxiv
DO  - 10.64898/2026.10.20.760516
UR  - https://www.biorxiv.org/content/10.64898/2026.10.20.760516v1
AB  - Plaque psoriasis is a chronic inflammatory skin disease characterized by itchy, scaly skin. Although there is currently no cure for this disease, it can be managed with medication, such as phosphodiesterase-4 (PDE4) inhibitors. Current PDE4 inhibitors are limited and show adverse effects. With the goal to develop better PDE4 inhibitors for the treatment of plaque psoriasis, two novel drug candidates were designed with computational studies, and observed to have better ADMET properties compared to Roflumilast. A homology analysis was performed to determine the best model organism for preclinical studies of the novel candidates.
ER  -

Abstract

Related

Cite